Vuity™
Drug - Vuity™ (pilocarpine 1.25% ophthalmic solution) [Abbvie Inc.]
April 2022
Therapeutic area - Ophthalmics Agents
Initial approval criteria
- Patient has a diagnosis of presbyopia AND
- Patient is 40 to 55 years of age AND
- Vuity is prescribed by or in consultation with an optometrist or ophthalmologist AND
- Patient has a documented contraindication and/or failure of corrective lenses (eyeglasses or contacts) to resolve presbyopia symptoms AND
- Patient does not have a hypersensitivity to pilocarpine or any other component of the product AND
- Patient does not have glaucoma or ocular hypertension AND
- Patient will NOT receive concomitant treatment with any other ophthalmic pilocarpine formulation AND
- Patient has been counseled to seek immediate medical care if they experience sudden onset of vision loss AND
- Patient does not have iritis AND
- For contact wearers, the patient has been advised to remove contact lenses prior to instillation of Vuity drops and to wait 10 minutes after dosing to reinsert contact lenses.
- Initial approval is for 6 months
Renewal criteria
- Patient continues to meet the above criteria AND
- Patient experienced disease response as indicated by improvement in presbyopia AND
- Patient is free of unacceptable toxicity from the drug (e.g., retinal detachment event, iritis, hypersensitivity to Vuity)
- Renewal is for 12 months
Quantity limits
- 1 bottle (2.5 mL) per 25 days
Questions?
MHCP Provider Resource Center 651-431-2700 or 1-800-366-5411